Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)

By Karen Loudon / April 26, 2024
Ian Nisbet, PhD Chief Operating Officer, Cartherics Pty Ltd As published in pharmaphorum  Background The recent acquisition of ImmunoGen by...
Read More

Cartherics enters into Collaborative Research Agreement with TiCARos

By Karen Loudon / April 2, 2024
  Melbourne, Australia, 2 April 2024 –  Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the...
Read More

Cartherics executes Option Agreement with The Ohio State University

By Karen Loudon / March 20, 2024
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS Melbourne, Australia, 20 March 2024 –  Cartherics Pty Ltd (“Cartherics” or...
Read More